May 13, 2025

Genomate Health Raises $2M, Enters US Market with Precision Oncology Clinical Decision Support Tool

May 13, 2025

Genomate Health, a spinoff from Hungarian medical technology firm Oncompass Medicine, said Monday that it has entered the US market and will begin offering its genomics-based precision oncology drug selection platform, a clinical decision support system.

Other Media Coverage

See all

Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 4, 2024

Read Article

DiMe and Moffitt Cancer Center to Co-Host Cancer Moonshot's New CancerX Public-Private Partnership

March 23, 2023

Read Article

Webinar: DrugBank In Conversation: AI in Precision Oncology, with Genomate

August 30, 2023

Read Article

Other Resources

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.